These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24306948)

  • 41. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
    McDonald H; Diamantopoulos A; Wells P; Lees M; Folkerts K; Forster F; Ananthapavan J
    J Med Econ; 2012; 15(5):817-28. PubMed ID: 22494267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
    Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
    Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivaroxaban in acute coronary syndromes--is it prime time?
    Asrar ul Haq M; van Gaal WJ
    Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial.
    Puskas J; Gerdisch M; Nichols D; Quinn R; Anderson C; Rhenman B; Fermin L; McGrath M; Kong B; Hughes C; Sethi G; Wait M; Martin T; Graeve A;
    J Thorac Cardiovasc Surg; 2014 Apr; 147(4):1202-1210; discussion 1210-1. PubMed ID: 24512654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
    Turpie AG; Haas S; Kreutz R; Mantovani LG; Pattanayak CW; Holberg G; Jamal W; Schmidt A; van Eickels M; Lassen MR
    Thromb Haemost; 2014 Jan; 111(1):94-102. PubMed ID: 24154549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Inhibition of thrombocyte aggregation after heart valve replacement].
    von Schacky C
    Z Kardiol; 1998; 87 Suppl 4():46-55. PubMed ID: 9857467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
    Wolzt M; Gouya G; Kapiotis S; Becka M; Mueck W; Kubitza D
    Thromb Res; 2013 Aug; 132(2):240-7. PubMed ID: 23786894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A model of heterotopic aortic valve replacement: a critique.
    Silverman NA
    J Surg Res; 2007 Aug; 141(2):133. PubMed ID: 17583741
    [No Abstract]   [Full Text] [Related]  

  • 53. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years.
    Stassano P; Di Tommaso L; Monaco M; Iorio F; Pepino P; Spampinato N; Vosa C
    J Am Coll Cardiol; 2009 Nov; 54(20):1862-8. PubMed ID: 19892237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
    Lassen MR; Gent M; Kakkar AK; Eriksson BI; Homering M; Berkowitz SD; Turpie AG
    J Bone Joint Surg Br; 2012 Nov; 94(11):1573-8. PubMed ID: 23109641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of an animal experimental model for a bileaflet mechanical heart valve prosthesis.
    Choo SJ; Kim KI; Park NH; Song JM; Choi IC; Shim JY; Lee SK; Kwon YJ; Kim CN; Lee JW
    J Korean Med Sci; 2004 Feb; 19(1):37-41. PubMed ID: 14966339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses.
    García-Rinaldi R; Carro-Pagán C; Schaff HV; McKellar SH; Thompson JL; Quiñones J; Rodríguez-Acosta JF
    J Heart Valve Dis; 2009 Nov; 18(6):617-25; discussion 626. PubMed ID: 20099710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Response to "Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban".
    Turpie AG
    J Clin Pharmacol; 2011 Jul; 51(7):1122-3. PubMed ID: 21666147
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
    Becker EM; Perzborn E; Klipp A; Lücker C; Bütehorn U; Kast R; Badimon JJ; Laux V
    J Thromb Haemost; 2012 Dec; 10(12):2470-80. PubMed ID: 23083002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
    Baruch L; Sherman O
    Ann Pharmacother; 2013 Sep; 47(9):1210-2. PubMed ID: 24259738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.